01
Petar Bast
CEO
15+ years in the generics pharmaceutical industry. Former Vice President in BD at Actavis/Allergan.
C The people behind Omet
Our Team
The Omet Pharma team consists of seasoned commercial and technical experts with deep roots in the generics and pharmaceutical industry, based across Sweden, Denmark, Switzerland and Bulgaria.
02
Anders Jungbeck
Co-Founder & Board Member
35+ years in the generics pharmaceutical industry. Former CEO of Scandinavia and Northern EU at Actavis.
03
Silvester Kovachev
Head of Product Acquisition
30+ years of experience in the pharmaceutical industry. Former global VP of in-licensing at Actavis.
04
Henriette Sidenius
Head of Commercial
20+ years in the pharmaceutical industry. Ex-Managing Director at Actavis, GM Nordics at Glenmark and Commercial Director Scandinavia at Orion.
05
Petya Ivanova
Head of SCM & Launches
10+ years in SCM in Pan-European generics companies. 5+ years in procurement and contract management in the generics industry.
06
Marcus Johansson
Responsible Person
10+ years within the Medical Device and Medicinal industries. Former QC Manager at Gambro Lundia (Baxter).
07
Krasimira Lesova
Head of Finance
10+ years in Finance, FP&A and accounting in an original pharmaceutical company. 4 years accounting in a Big 4 audit company.
08
Stanimira Tsepova
Regulatory Affairs Manager
10+ years of pharmaceutical industry experience. 6+ years regulatory affairs experience in generics companies.
09
Asya Pavlova
Business Development
13+ years in the pharmaceutical industry across business planning & analysis, contracts and pricing, and competitive intelligence. Previously at Amgen and Teva/Actavis Generics.
10
Stefan Hadjiolov
Regulatory Affairs Manager
MD with 5+ years in medical and regulatory affairs, including regulatory strategy and dossier development for generic and hybrid medicines. Previously Medical & Regulatory Affairs Manager at Antibiotic Razgrad.
next Keep exploring
Up next
Quality & Safety
How side effects, quality complaints and product enquiries are handled, with the reporting route for each national medicines authority.